Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vaccine Discoveries Drive India’s Biotech Industry (India)

This article was originally published in PharmAsia News

Executive Summary

India's biotechnology companies count on the vaccines end of their business to drive the rest of their work in developing therapeutics, diagnostics and other segments. The vaccines segment accounts for more than 70 percent of biotech work in the country, increasing at a rate of more than 30 percent a year, reaching the $3 billion mark by 2010. The biotechs rely heavily on public institutions to do early-stage research, such as producing cell lines, so the companies can focus on process and clinical development. That trend was begun by Shantha Biotechnic's work in developing a hepatitis B vaccine based on earlier work by the Centre for Cellular and Molecular Biology. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts